2024
Changes in lung function and mortality risk in patients with idiopathic pulmonary fibrosis (IPF)
Oldham J, Neely M, Wojdyla D, Gulati M, Li P, Patel D, Palmer S, Todd J, Patel D. Changes in lung function and mortality risk in patients with idiopathic pulmonary fibrosis (IPF). 2024, pa674. DOI: 10.1183/13993003.congress-2024.pa674.Peer-Reviewed Original ResearchPlasma collagen neoepitopes are associated with multiorgan disease in the ACCESS and GRADS sarcoidosis cohorts
Sand J, Jessen H, Leeming D, Yu S, Lee C, Hu B, Sun Y, Adams T, Pivarnik T, Liu A, Woo S, McGovern J, Fiorini V, Saber T, Higuero-Sevilla J, Gulati M, Kaminski N, Damsky W, Shaw A, Mohanty S, Goobie G, Zhang Y, Herzog E, Ryu C. Plasma collagen neoepitopes are associated with multiorgan disease in the ACCESS and GRADS sarcoidosis cohorts. Thorax 2024, thorax-2023-221095. PMID: 39117421, DOI: 10.1136/thorax-2023-221095.Peer-Reviewed Original ResearchSarcoidosis cohortMultiorgan diseasePRO-C3Interleukin-4Case Control Etiologic Study of SarcoidosisPlasma levels of interleukin-4Alpha-1 antitrypsin deficiencyLevels of interleukin-4Pathogenesis of sarcoidosisC6MC3MHealthy control patientsStudy of sarcoidosisGenomic researchAbnormal extracellular matrixAssociated with dermatological diseaseCollagen degradationScadding stageCorticosteroid useComplex diseasesPRO-C6Control patientsIL-13IL-5IL-9Innate Immune Effects of Α1-adrenoreceptor Antagonism in Sarcoidosis
Saber T, Yu S, Lee C, Fiorini V, Mcgovern J, Woo S, Gulati M, Ryu C, Herzog E. Innate Immune Effects of Α1-adrenoreceptor Antagonism in Sarcoidosis. 2024, a2531-a2531. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2531.Peer-Reviewed Original ResearchTelomere Attrition Is Associated With Sarcoidosis
Gandhi S, Lee C, Yu S, Saber T, Woo S, Mcgovern J, Fiorini V, Gulati M, Herzog E, Ryu C. Telomere Attrition Is Associated With Sarcoidosis. 2024, a2530-a2530. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2530.Peer-Reviewed Original ResearchLong-term Air Pollution Exposure Is Associated With Increased Severity of Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry
Sack C, Wojdyla D, Macmurdo M, Gassett A, Kaufman J, Raghu G, Redlich C, Li P, Olson A, Leonard T, Todd J, Neely M, Snyder L, Gulati M, on behalf of the IPF-PRO Registry investigators. Long-term Air Pollution Exposure Is Associated With Increased Severity of Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry. 2024, a1798-a1798. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1798.Peer-Reviewed Original ResearchDevelopment and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease
Swaminathan A, McFatrich M, Mkumba L, Wright L, Redlich C, Snyder L, Reeve B, Patel D, Gulati M. Development and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease. Respiratory Research 2024, 25: 372. PMID: 39407223, PMCID: PMC11481565, DOI: 10.1186/s12931-024-03000-z.Peer-Reviewed Original ResearchConceptsCognitive interviewsContent validityExposure questionnaireMultidisciplinary teamSemi-structured interview guideEvidence of content validityFibrosing ILDsInterstitial lung diseaseRelevant exposuresFibrotic interstitial lung diseaseClinically relevant exposuresTrained interviewersInterview guideAssessment QuestionnaireQuestionnaireInterviewsLung diseaseAdultsTeamClinicPatientsSource of misunderstandingOccupational inhalation exposureValidityDisease
2023
Circulating Mitochondrial DNA Is Associated With High Levels of Fatigue in Two Independent Sarcoidosis Cohorts
Fiorini V, Hu B, Sun Y, Yu S, McGovern J, Gandhi S, Woo S, Turcotte-Foster S, Pivarnik T, Khan Z, Adams T, Herzog E, Kaminski N, Gulati M, Ryu C. Circulating Mitochondrial DNA Is Associated With High Levels of Fatigue in Two Independent Sarcoidosis Cohorts. CHEST Journal 2023, 165: 1174-1185. PMID: 37977267, PMCID: PMC11110677, DOI: 10.1016/j.chest.2023.11.020.Peer-Reviewed Original ResearchPatient-related outcome measuresToll-like receptor 9Fatigue Assessment ScalePlasma mtDNA concentrationsTLR9 activationSarcoidosis patientsMtDNA concentrationsMulti-organ sarcoidosisCommon chief complaintInnate immune activationNovel therapeutic strategiesDomains of fatigueSevere clinical phenotypePsychobiologic mechanismsSarcoidosis cohortScadding stageCorticosteroid useCytokine levelsExtrapulmonary diseaseProspective cohortFAS scoresPulmonary fibrosisChief complaintImmune activationPatient populationEVALUATION OF CONTENT VALIDITY OF A NEW EXPOSURE ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH FIBROSING INTERSTITIAL LUNG DISEASES
SWAMINATHAN A, MCFATRICH M, MKUMBA L, WRIGHT L, REDLICH C, SNYDER L, REEVE B, OLSON A, GULATI M. EVALUATION OF CONTENT VALIDITY OF A NEW EXPOSURE ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH FIBROSING INTERSTITIAL LUNG DISEASES. CHEST Journal 2023, 164: a5103-a5104. DOI: 10.1016/j.chest.2023.07.3304.Peer-Reviewed Original ResearchProteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome
Singh I, Leitner B, Wang Y, Zhang H, Joseph P, Lutchmansingh D, Gulati M, Possick J, Damsky W, Hwa J, Heerdt P, Chun H. Proteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in Post Acute Sequelae of SARS‐CoV‐2 infection (PASC) syndrome. Pulmonary Circulation 2023, 13: e12220. PMID: 37091121, PMCID: PMC10113513, DOI: 10.1002/pul2.12220.Peer-Reviewed Original ResearchInvasive cardiopulmonary exercise testPASC patientsPost-acute sequelaeAcute sequelaeInfection syndromeUnexplained exertional intoleranceCardiopulmonary exercise testSystemic oxygen deliveryPersistent inflammatory stateVenous blood plasmaExertional intolerancePeak exerciseEndothelial dysfunctionHemodynamic profileInflammatory stateExercise testFibrotic processPathophysiological hallmarkAberrant protein expressionExpression of proteinsOxygen deliveryOxygen extractionProteomic profilingPatientsPhysiologic responsesAutoimmune comorbidities associated with sarcoidosis: a case-control study in the All of Us research program
Murphy M, Edemobi P, Leasure A, Gulati M, Miller E, Damsky W, Cohen J. Autoimmune comorbidities associated with sarcoidosis: a case-control study in the All of Us research program. Rheumatology Advances In Practice 2023, 7: rkad030. PMID: 38606002, PMCID: PMC11007907, DOI: 10.1093/rap/rkad030.Peer-Reviewed Original ResearchCase-control studyAutoimmune diseasesSarcoidosis patientsMultivariable analysisOdds ratioSarcoidosis casesUs Research ProgramDiverse cohortConcomitant autoimmune diseasesRace-matched controlsMultiple autoimmune diseasesAutoimmune comorbiditiesSarcoidosisPatientsLogistic regressionDiseaseSmall sample sizeCareful screeningCohortAssociationSample sizeComposite variablePrior studiesComorbiditiesStudy“Long Haulers”
Lutchmansingh D, Sevilla J, Possick J, Gulati M. “Long Haulers”. Seminars In Respiratory And Critical Care Medicine 2023, 44: 130-142. PMID: 36646091, DOI: 10.1055/s-0042-1759568.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPost-COVID conditionsAcute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionSARS-CoV-2 infectionChronic COVID-19Long-haul COVIDOngoing interventional trialsLong-term morbidityCoronavirus disease 2019Multiple organ systemsInterventional trialsLong COVIDTreatment algorithmNeuropsychiatric sequelaePostacute sequelaeRisk factorsObservational studyDisease 2019Long-term effectsSurvivors' qualityClinical protocolsLong haulersOrgan systems
2022
Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study
Strykowski R, Patel DC, Neto MR, Hena KM, Gulati M, Maier LA, Patterson K. Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study. BMJ Open Respiratory Research 2022, 9: e001254. PMID: 35882424, PMCID: PMC9329732, DOI: 10.1136/bmjresp-2022-001254.Peer-Reviewed Original ResearchConceptsLung functionRespiratory infectionsLocal institutional review board approvalFibrotic pulmonary sarcoidosisInstitutional review board approvalNon-infected patientsInterstitial lung diseaseRespiratory viral illnessReview board approvalViral infectious diseasesImpact of infectionPulmonary sarcoidosisViral illnessClinical courseInfectious eventsStudy entryStudy cohortPoor outcomeProspective studyLung diseaseLong-term impactLife measuresSarcoidosisHigh riskGeneral populationOccupational and environmental exposures in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study
Ryan SM, Mroz MM, Herzog EL, Ryu C, Fingerlin TE, Maier LA, Gulati M. Occupational and environmental exposures in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study. Respiratory Medicine 2022, 200: 106923. PMID: 35932543, DOI: 10.1016/j.rmed.2022.106923.Peer-Reviewed Original ResearchConceptsAlpha-1 antitrypsin deficiencyCardiac sarcoidosisSarcoidosis StudyAntitrypsin deficiencyRadiation exposureNon-cardiac sarcoidosisNon-chronic diseasesMultiple comparisonsEnvironmental exposure dataExtrapulmonary diseasePulmonary involvementGranulomatous disorderSarcoidosis phenotypesRisk factorsSpecific disease phenotypesStage 0Number of exposuresSarcoidosisExposure assessment toolsSusceptible individualsSpecific exposuresDiseaseEnvironmental exposuresExposure dataIndividual exposureInhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis
Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nature Communications 2022, 13: 3140. PMID: 35668129, PMCID: PMC9170782, DOI: 10.1038/s41467-022-30615-x.Peer-Reviewed Original ResearchConceptsType 1 immunityInternal organ involvementOrgan involvementT cell-derived IFNIdiopathic inflammatory disorderOpen-label trialMonths of treatmentType 1 cytokinesJanus kinase inhibitorImmunologic changesLongstanding sarcoidosisSarcoidosis activitySarcoidosis symptomsClinical improvementCutaneous sarcoidosisSecondary outcomesComplete responsePrimary outcomeTofacitinib treatmentActivity scoreCytokine mediatorsIL-12IL-15IL-6Inflammatory disordersDisparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry
Swaminathan A, Hellkamp A, Neely M, Bender S, Paoletti L, White E, Palmer S, Whelan T, Dilling D, Baker A, Beegle S, Belperio J, Condos R, Cordova F, Culver D, Fitzgerald J, Flaherty K, Gibson K, Gulati M, Guntupalli K, Gupta N, Case A, Hotchkin D, Huie T, Kaner R, Kim H, Lancaster L, Lasky J, Lee D, Liesching T, Lipchik R, Lobo J, Luckhardt T, Mageto Y, Menon P, Morrison L, Namen A, Oldham J, Paul T, Zhang D, Porteous M, Raj R, Ramaswamy M, Russell T, Sachs P, Safdar Z, Shafazand S, Siddiqi A, Sigal B, Strek M, Suliman S, Tabak J, Walia R. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Annals Of The American Thoracic Society 2022, 19: 981-990. PMID: 35073248, PMCID: PMC9169123, DOI: 10.1513/annalsats.202105-589oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisMedian ZIP code incomeZip code incomeLung transplant programsLung transplantProspective outcomes registryClinical characteristicsOutcomes RegistryPulmonary fibrosisTransplant programsSocial determinantsLung transplant centersDisease severity measuresIPF-PRO RegistryLikelihood of deathYears of ageLung transplantationPrespecified covariatesU.S. registriesDifferential associationsTransplant centersTransplant eligibilityClinical trialsTherapeutic modalitiesPatientsCough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease Data From the Pulmonary Fibrosis Foundation Patient Registry
Lee J, White E, Freiheit E, Scholand M, Strek M, Podolanczuk A, Patel N, Foundation P, Bascom R, Belloli E, Bhatt N, Bhorade S, Case A, Castriotta R, Criner G, Danoff S, De Andrade J, Desai A, Glassberg M, Glazer C, Gulati M, Gupta N, Hamblin M, Huie T, Kaner R, Kass D, Kim H, Kreider M, Lancaster L, Lasky J, Limper A, Montesi S, Mooney J, Morrison L, Nambiar A, Nathan S, Natt B, Paul T, Perez R, Podolanczuk A, Raghu G, Scholand M, Shifren A, Strek M, Todd N, Walia R, Weight S, Whelan T, Wolters P. Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease Data From the Pulmonary Fibrosis Foundation Patient Registry. CHEST Journal 2022, 162: 603-613. PMID: 35337809, PMCID: PMC9808640, DOI: 10.1016/j.chest.2022.03.025.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseCough-specific QoLLeicester Cough QuestionnaireLung transplantationRespiratory hospitalizationsHigh riskPatient factorsLung diseaseDisease progressionLCQ scoreDisease severityMultivariable Cox regression modelsMultivariable proportional hazards modelsPatient-centered clinical outcomesBaseline disease severityGastroesophageal reflux diseaseHealth-related qualityRespiratory-related hospitalizationsCough-specific qualityIdiopathic pulmonary fibrosisPulmonary function parametersCox regression modelProportional hazards modelMultivariable proportional odds modelProportional odds modelOccupational Exposome and Lung Health
MacMurdo M, Culver D, Gulati M. Occupational Exposome and Lung Health. Respiratory Medicine 2022, 51-91. DOI: 10.1007/978-3-030-90185-1_4.Peer-Reviewed Original ResearchOccupational lung diseaseLung diseaseChronic occupational lung diseaseSecondary disease preventionPublic health providersRespiratory morbidityLung healthRespiratory healthWorkplace exposuresHealth providersDisease preventionDiseaseMultidisciplinary approachKey pathwaysPreventionExposomeHealthExposureMorbiditySignificant contributorMortalityCliniciansCorrection to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
Todd JL, Neely ML, Overton R, Mulder H, Roman J, Lasky JA, de Andrade JA, Gulati M, Huang H, Leonard TB, Hesslinger C, Noth I, Belperio JA, Flaherty KR, Palmer SM. Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort. Lung 2022, 200: 19-19. PMID: 35166906, PMCID: PMC8881254, DOI: 10.1007/s00408-022-00516-3.Peer-Reviewed Original ResearchAssociation of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort
Todd JL, Neely ML, Overton R, Mulder H, Roman J, Lasky JA, de Andrade JA, Gulati M, Huang H, Leonard TB, Hesslinger C, Noth I, Belperio JA, Flaherty KR, Palmer SM. Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort. Lung 2022, 200: 11-18. PMID: 35066606, PMCID: PMC8881240, DOI: 10.1007/s00408-021-00505-y.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisLung transplantRespiratory deathsPulmonary fibrosisClinical measuresOptimism-corrected C-indexRisk of mortalityVariable clinical courseIPF-PRO RegistryRegistry cohortComposite outcomeClinical courseMultivariable analysisUnivariable analysisPatient outcomesC-indexCirculating proteinFatal diseaseTransplantPatientsDeathFibrosisOutcomesAssociationRegistryOccupational Interstitial Lung Disease
Gulati M, Maier L. Occupational Interstitial Lung Disease. 2022, 368-380. DOI: 10.1016/b978-0-12-801238-3.11503-x.Peer-Reviewed Original ResearchInterstitial lung diseaseLung diseaseRelated interstitial lung diseaseOccupational interstitial lung diseaseIdiopathic interstitial pneumoniaSecondary prevention programsRespiratory surveillance programLocal health departmentsDisease-exposure relationshipsCoal workers' pneumoconiosisInterstitial pneumoniaPathologic patternsPersonal protection equipmentDifferential diagnosisHealth departmentsPrevention programsSpecific exposuresSurveillance programConsideration of exposureHealth agenciesDiseaseRelevant exposuresExposure relationshipExposure historySimilar diseases